Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. 

 

Traditional AVA workflows require numerous parallel and sequential assays, often taking weeks to complete and contributing heavily to manufacturing timelines and operational cost. Despite their complexity, these approaches can still produce false negatives and false positive results.

 

In this webinar, supported by ViruSure, a global leader in pathogen safety testing, shares how it works on transforming this landscape by launching the world’s first GMP validated AVA detection test based on Oxford Nanopore sequencing. This first in class solution consolidates multiple assays into a single, comprehensive test, enabling broader viral detection, faster time to result, and more confident decision making in regulated QC environments.

 

Attendees will learn how real-time nanopore sequencing can improve the ability to distinguish true contaminants from background signals, significantly reducing the frequency of false negatives and false positives and the costly investigations they trigger.

 

 

You will learn:

• How NGS sequencing can be used to improve testing timelines in an AVA test

• How a single, comprehensive test can enable broader viral detection

• The benefits of sequencing to support operational efficiency, stronger supply chain resilience, and more ethical testing practices